- Home
- Publications
- Publication Search
- Publication Details
Title
Checkpoint inhibition in pediatric hematologic malignancies
Authors
Keywords
-
Journal
PEDIATRIC HEMATOLOGY AND ONCOLOGY
Volume 34, Issue 6-7, Pages 379-394
Publisher
Informa UK Limited
Online
2017-12-01
DOI
10.1080/08880018.2017.1383542
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression
- (2017) Brooke E. Howitt et al. OncoImmunology
- Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation
- (2016) J A Yared et al. BONE MARROW TRANSPLANTATION
- PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- (2016) Sara Gandini et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma
- (2016) H. Y. Yoo et al. HAEMATOLOGICA
- PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
- (2016) Junzo Hamanishi et al. International Journal of Clinical Oncology
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Classification and characterization of microsatellite instability across 18 cancer types
- (2016) Ronald J Hause et al. NATURE MEDICINE
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers
- (2016) Takahiro Aoki et al. PEDIATRIC BLOOD & CANCER
- Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
- (2016) Jose Caetano Villasboas et al. Oncotarget
- Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma
- (2016) H. Y. Yoo et al. HAEMATOLOGICA
- Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy
- (2016) Dickran Kazandjian et al. JAMA Oncology
- Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
- (2016) Giuseppe V. Masucci et al. Journal for ImmunoTherapy of Cancer
- Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
- (2015) M. S. Merchant et al. CLINICAL CANCER RESEARCH
- T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
- (2015) Frauke M. Schnorfeil et al. Journal of Hematology & Oncology
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Integrated molecular analysis of adult T cell leukemia/lymphoma
- (2015) Keisuke Kataoka et al. NATURE GENETICS
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol
- (2014) Hideki Nakayama et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chronic TLR Signaling Impairs the Long-Term Repopulating Potential of Hematopoietic Stem Cells of Wild Type but Not Id1 Deficient Mice
- (2013) Ying Zhao et al. PLoS One
- Myeloid leukemia cells with a B7-2+subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands
- (2012) Yusuf Dolen et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma
- (2012) Zhi-Zhang Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Soluble Form of CTLA-4 Is Present in Paediatric Patients with Acute Lymphoblastic Leukaemia and Correlates with CD1d+ Expression
- (2012) Rita Simone et al. PLoS One
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Chronic Exposure to a TLR Ligand Injures Hematopoietic Stem Cells
- (2011) B. L. Esplin et al. JOURNAL OF IMMUNOLOGY
- Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
- (2010) Q. Zhou et al. BLOOD
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials
- (2010) A Sander et al. LEUKEMIA
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study
- (2010) Matthew F. Gorman et al. PEDIATRIC BLOOD & CANCER
- PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
- (2009) L. Zhang et al. BLOOD
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines
- (2009) William D. Hastings et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
- (2009) J. F. Grosso et al. JOURNAL OF IMMUNOLOGY
- Twelve immunotherapy drugs that could cure cancers
- (2008) Martin A. ‘Mac’ Cheever IMMUNOLOGICAL REVIEWS
- B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease Recurrence
- (2008) Jonathan C. Routh et al. JOURNAL OF UROLOGY
- CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy
- (2008) A Pérez-García et al. LEUKEMIA
- Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-γ
- (2008) Selim Corm et al. LEUKEMIA RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now